Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

NCT00576056 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Bayer Healthcare is no supplying the study drug

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Sorafenib
DRUG: TACE

Sponsor

University of Pittsburgh

Collaborators

[object Object]